Neoplasms, Unknown Primary — Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Citation(s)
A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site